JSR Expands its Biomedical Business by Investing in BIA Separations' Unique Purification Technology
|| Print ||
|Wednesday, 18 January 2012 10:00 (UTC + 1)|
Tokyo, Japan, January 18, 2012/ B3C newswire / – JSR Corporation (Head Office: Minato-Ku, Tokyo, President: Mitsunobu Koshiba) and BIA Separations (Head Office: Villach, Managing Director and CEO: Aleš Štrancar) announced that they have entered a strategic partnership which includes a minor equity position by JSR on November 14th 2011.
As a result of this investment, JSR and BIA Separations have started a joint global marketing and sales effort and collaborative R&D activities in the area of downstream purification as part of the manufacturing of vaccine, DNA and antibody based medicines.
From JSR’s perspective, teaming up with BIA Separations will give JSR access to a unique and leading edge technology in the field of downstream purification of large bio-molecules. Combining this technology with JSR’s proprietary Protein A media, we offer the bio pharmaceutical industry a faster, more reliable downstream purification process at a lower cost of ownership. This will contribute to making advanced treatments accessible to a larger part of the human society.
BIA Separations recognizes that JSR Corporation is a leading polymer chemistry manufacturer with a very strong commitment to the life sciences industry. JSR’s global presence in the local markets and JSR’s expertise in the field of consistent high quality volume manufacturing will help BIA Separations to successfully grow its business while maintaining its technological leadership. This partnership is a very important message to the industry as it secures the long term presence of BIA Separations and its technology and products on the market.
About BIA Separations